SHELLEY MALLARD: Open Payments
NPI 1568404457 · WAYNESBORO, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$407 in 22 payments from 15 companies in 2025. Trend: 2023 $410 · 2024 $402 · 2025 $407
Food & beverage: $407
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $64 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $59 |
| Novo Nordisk Inc | 2 | $34 |
| Abbott Laboratories | 2 | $34 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $29 |
| Axsome Therapeutics, Inc. | 1 | $28 |
| Lundbeck LLC | 1 | $28 |
| Vanda Pharmaceuticals Inc. | 1 | $19 |
| AstraZeneca Pharmaceuticals LP | 1 | $18 |
| ABBVIE INC. | 1 | $17 |
Products named: CAPLYTA, Kerendia, Wegovy, FREESTYLE LIBRE 3, XIFAXAN, Auvelity, REXULTI, FANAPT.
Industry payments across GA — which companies pay providers there.
